Intensity Therapeutics Inc - INTS Net earnings per share for the last four quarters

Official company branding of Intensity Tx (INTS)

Intensity Therapeutics is integrating ESG principles into the development of oncology drugs to minimize harmful emissions. The 12-month YoY earnings per share growth rate reflects fundamental stability, where 72.40 represents the current value of the metric. The company is developing an intratumoral method to combat metastases, and the publication of fresh clinical data serves as the primary driver of market optimism.

Intensity Therapeutics, Inc. (INTS) Earnings per share for the last twelve months: for the period 11/23/2025 - 11/15/2026

INTS (Intensity Therapeutics Inc): analytical breakdowns and indicator data

- current price and projected stock value:
Price Performance Chart intensitytherapeutics.com|INTS - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization INTS|INTS - Total Company Value
- book value of equity indicators:
Accounting Value per Share Intensity Therapeutics|INTS - Company Book Value|Market Cap to Net Assets Ratio intensitytherapeutics.com|INTS - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Intensity Therapeutics|INTS - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Intensity Therapeutics, Inc.|INTS - Company Debts|Debts to Book Value Intensity Therapeutics|INTS - Company Long-Term Liabilities|Short-Term Indebtedness Intensity Therapeutics|Intermediate Liquidity Ratio intensitytherapeutics.com
- earnings and market multiples details:
INTS - Net Profit|Expected Net Income Intensity Therapeutics|INTS - P/E Multiple|Projected Price to Earnings Ratio Intensity Therapeutics, Inc.|INTS - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Intensity Tx|INTS - Operating profit EBITDA|Net earnings per share (EPS TTM) Intensity Therapeutics|INTS - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months intensitytherapeutics.com|INTS - Net earnings per share growth this year|Expected net earnings per share growth next year Intensity Therapeutics
- revenue and sales details:
INTS - Revenue and Sales Volume|Company Future Sales Intensity Therapeutics, Inc.|INTS - Price-to-Revenue Ratio|Market Cap to Projected Revenue Intensity Therapeutics
Initial company analysis:INTS, Intensity Therapeutics
Mass-produced product of Intensity Therapeutics, Inc.

Investors determine an asset's margin of safety through net income per share dynamics, where the calculated TTM growth reveals either systemic degradation or sustainable business development. For Intensity Therapeutics (INTS), which is developing a method for the local destruction of tumors, the YoY TTM EPS growth efficiency metric reflects the innovative therapy's ability to generate value, characterizing Intensity Therapeutics as a high-risk venture asset.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Earnings per one share for the last 12 months|NextCure Inc - Net earnings per share for the last 12 months|Leap Therapeutics, Inc. (LPTX) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months